Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of EUR 151.87 million. The enterprise value is 102.09 million.
Market Cap | 151.87M |
Enterprise Value | 102.09M |
Important Dates
The last earnings date was Thursday, March 27, 2025.
Earnings Date | Mar 27, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 83.81 million shares outstanding. The number of shares has increased by 0.74% in one year.
Current Share Class | n/a |
Shares Outstanding | 83.81M |
Shares Change (YoY) | +0.74% |
Shares Change (QoQ) | +0.44% |
Owned by Insiders (%) | 2.39% |
Owned by Institutions (%) | 1.53% |
Float | 34.42M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 1.54 |
PS Ratio | 7.30 |
PB Ratio | 16.66 |
P/TBV Ratio | 17.19 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.06 |
EV / Sales | 5.07 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -14.01 |
Financial Position
The company has a current ratio of 2.60, with a Debt / Equity ratio of 3.51.
Current Ratio | 2.60 |
Quick Ratio | 2.60 |
Debt / Equity | 3.51 |
Debt / EBITDA | n/a |
Debt / FCF | -4.25 |
Interest Coverage | -23.71 |
Financial Efficiency
Return on equity (ROE) is -162.91% and return on invested capital (ROIC) is -48.98%.
Return on Equity (ROE) | -162.91% |
Return on Assets (ROA) | -21.84% |
Return on Invested Capital (ROIC) | -48.98% |
Return on Capital Employed (ROCE) | -66.06% |
Revenue Per Employee | 111,166 |
Profits Per Employee | -273,320 |
Employee Count | 181 |
Asset Turnover | 0.14 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.35% in the last 52 weeks. The beta is 0.86, so Innate Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.86 |
52-Week Price Change | -17.35% |
50-Day Moving Average | 1.93 |
200-Day Moving Average | 1.90 |
Relative Strength Index (RSI) | 38.31 |
Average Volume (20 Days) | 107,145 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innate Pharma had revenue of EUR 20.12 million and -49.47 million in losses. Loss per share was -0.61.
Revenue | 20.12M |
Gross Profit | -31.86M |
Operating Income | -51.58M |
Pretax Income | -49.47M |
Net Income | -49.47M |
EBITDA | -49.58M |
EBIT | -51.58M |
Loss Per Share | -0.61 |
Balance Sheet
The company has 80.77 million in cash and 31.00 million in debt, giving a net cash position of 49.78 million or 0.59 per share.
Cash & Cash Equivalents | 80.77M |
Total Debt | 31.00M |
Net Cash | 49.78M |
Net Cash Per Share | 0.59 |
Equity (Book Value) | 8.83M |
Book Value Per Share | 0.11 |
Working Capital | 52.76M |
Cash Flow
In the last 12 months, operating cash flow was -6.90 million and capital expenditures -391,000, giving a free cash flow of -7.29 million.
Operating Cash Flow | -6.90M |
Capital Expenditures | -391,000 |
Free Cash Flow | -7.29M |
FCF Per Share | -0.09 |
Margins
Gross margin is -158.34%, with operating and profit margins of -256.32% and -245.87%.
Gross Margin | -158.34% |
Operating Margin | -256.32% |
Pretax Margin | -245.87% |
Profit Margin | -245.87% |
EBITDA Margin | -246.41% |
EBIT Margin | -256.32% |
FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.74% |
Shareholder Yield | -0.74% |
Earnings Yield | -32.58% |
FCF Yield | -4.80% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -4.65. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -4.65 |
Piotroski F-Score | n/a |